Seaport Therapeutics
Seaport Therapeutics is seeking a strategic Associate Director, Regulatory Affairs to lead regulatory project teams and submission activities across assigned development programs. The role focuses on early development and Phase II proof-of-concept strategy for psychiatry and neurology therapies, ensuring seamless integration of regulatory requirements throughout the development lifecycle. This position requires deep expertise in global regulatory planning and collaboration with cross-functional teams to advance novel neuropsychiatric medicines.
Seaport Therapeutics is a biotechnology company developing novel neuropsychiatric medicines. The company applies its Glyph platform to advance potentially best-in-class therapeutics designed to improve efficacy and tolerability for patients with depression, anxiety, and other neuropsychiatric disorders.
Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
2 weeks ago
Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Jan 5, 2026
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
3 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Seaport Therapeutics.
Regulatory Affairs CMC Professional
gloorlang
Associate Director, Regulatory Affairs - CMC
PTC Therapeutics
Regulatory Affairs Lead
BeOne Medicines
Associate Director of CMC Regulatory Affairs
Monte Rosa Therapeutics, Inc
Senior Manager, Regulatory Strategy
Beeline Medicines
Director, Regulatory Affairs CMC
Corcept Therapeutics